A CITF-funded study, published as a preprint and not yet peer-reviewed, found that a surface plasmon resonance (SPR) sensor, which can provide quantitative biomolecular information and can be used in point-of-care settings, is a viable alternative for monitoring SARS-CoV-2 humoral immune responses.
A CITF-supported study, published in Frontiers in Immunology, found that delaying the second dose of an mRNA COVID-19 vaccine beyond approximately three months produced a more robust antibody response, despite this being a longer timeframe than was recommended by the vaccine manufacturers.
A CITF-funded study, published in Emergency Medicine Journal, using data from 47 Canadian Emergency Departments (ED), found that between March 1, 2020 and March 31, 2022, one in 10 patients had an unscheduled ED return visit for COVID-19 within 30 days and the median time to return was four days.
A CITF-funded study, published in Mucosal Immunology, found that the breadth and magnitude of T-cell responses were comparable whether individuals with two vaccine doses had a third vaccine dose or an Omicron breakthrough infection.
A CITF-funded study, published in The Journal of Immunology, reviewed the benefits and limitations of commonly used methods for assessing T cell immunity across SARS-CoV-2 studies.
A CITF-funded study’s cohort profile was published in BMJ Open, describing its study design, participant baseline characteristics, and ongoing data collection aimed at contributing data on effective SARS-CoV-2 immune responses conferred by infection and/or vaccination.
A CITF-funded study, published as a preprint and not yet peer-reviewed, found intriguing relationships -- correlates of infection or protection -- from all the COVID-19 data the researchers collected.
A CITF-supported study, published in Vaccines, suggested that higher antibody levels do not guarantee protection against COVID-19. Levels of antibodies to the original strain are not a reliable indicator to determine the need for or timing of booster dosing. Having received a bivalent vaccine (combining the original and Omicron strains) was associated with lack of a breakthrough infection during the Omicron BA.4/5 waves of the pandemic.
A CITF-funded study, published in Frontiers Immunology, highlights the interplay between SARS-CoV-2 vaccination, pre-existing immunity to common human endemic coronaviruses (HCoVs), and the resulting immune response to SARS-CoV-2.
A CITF-funded study, published in Transplantation, provided insights into the kinetics of variant-specific T-cell responses in recipients of solid organ transplants, with the aim of informing clinical and public health guidelines for immunocompromised populations.